Our results are consistent with previous studies reporting tumor-suppressive properties of SPDEF in cancers of the prostate, colon, and head and neck, where its loss was found to contribute to more aggressive disease phenotypes [6,7,8,9,10]. The gene discussed is SPDEF; the disease is neoplasm.